Key result
Prasugrel significantly reduced rates of cardiac ischemic events compared to clopidogrel in patients with ACS post-PCI, but significantly increased major bleeding.
Supports prasugrel over clopidogrel in ACS post-PCI with bleeding risk assessment; confirms net benefit of potent P2Y12 inhibition.
Prasugrel was associated with a statistically significant reduction in rates of cardiac ischemic events in patients with ACS who had undergone PCI. Rates of post-PCI death from cardiovascular causes, nonfatal MI, or nonfatal stroke were also significantly reduced with the use of prasugrel versus clopidogrel. Major bleeding was significantly increased with the use of prasugrel versus clopidogrel. Mortality did not differ significantly between the groups.
No takes yet. Share an insight, caveat, or question.
Solomon et al. (2010) studied Acute Coronary Syndrome (ACS) post-PCI. Prasugrel vs. Clopidogrel was evaluated on Cardiac ischemic events (including post-PCI death from cardiovascular causes, nonfatal MI, or nonfatal stroke). Prasugrel significantly reduced rates of cardiac ischemic events compared to clopidogrel in patients with ACS post-PCI, but significantly increased major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: